Lead Product(s): Proteolytic Enzymes Enriched in Bromelain
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
The study is expected to enroll 120 patients at approximately 20 clinical sites, primarily in U.S. Study participants are randomized to either EscharEx, placebo control or non-surgical soc of either enzymatic or autolytic debridement, at ratio of 3:3:2, with 3 month follow-up.